Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners

REFERENCES

• National Commission on Correctional Health Care. The Health Status of Soon-to-be-Released Inmates: A Report to Congress March, 2002. Available at: http://www.ncchc.org/pubs/pubs_stbr.html Accessed March 27, 2006.
   Google Scholar
• Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in cor-rectional facilities: a review. Clin Infect Dis. 2002;35(3):305–312.
   PubMed Web of Science ®Google Scholar
• Maruschak L. HIV in Prisons, 2000 [Bureau of Justice Sta-tistics bulletin]. Washington, DC: Department of Justice; October 2002. Available at: http://www.ojp.gov/bjs/pub/pdf/hivp00.pdf Accessed March 27, 2006.
   Google Scholar
• Palella FJ, Delaney K, Moorman A, HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853–860.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control (CDC). Decrease in AIDS-re-lated mortality in a state correctional system-New York, 1995–1998. MMWR Morb Mortal Wkly Rep. 1999;47(51–52): 1115-1117.
   Google Scholar
• Pollack H, Khoshnood K, Altice FL. Health care delivery strategies for criminal offenders. J Health Care Finance. 1999;26(1):63–77.
   PubMedGoogle Scholar
• Restum ZG. Public health implications of substandard correctional health care. Am J Public Health. 2005;95(10): 1689–1691.
   PubMed Web of Science ®Google Scholar
• Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004;38(12)1 754–1760.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006;296(7):769–781.
   PubMed Web of Science ®Google Scholar
• Riddler S, Haubrich R, DiRienzo G, et al, AIDS Clinical Tri-als Group 5142 Study Team. A prospective, randomized, phase III trial of NRTI-, Pl- and NNRTI-sparing regimens for initial treatment of HIV-1 infection-ACTG 5142. Paper presented at: XVI International AIDS Conference; August 13–18, 2006; Toronto, Ontario, Canada.
   Google Scholar
• Connecticut Department of Correction. July 1,2003 Statistics. Available at: http://www.doc.state.ctus/report/stat20030701.htm
   Google Scholar
• Altice FL, Mostashari F, Selwyn PA, et al. Predictors of HIV infection among newly sentenced male prisoners. J Acquir Immune Defic Syndr Hum Retroyirol. 1998 ;18(5):444–453.
   Web of Science ®Google Scholar
• Altice FL, Khoshnood K, Blankenship KM, et al. Determi-nants of HIV seroprevalence and seroincidence of new entrants to a women's prison. Paper presented at: XI Inter-national Conference on AIDS; 1996; Vancouver, Canada.
   Google Scholar
• US Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Panel on Clinical Practices for Treatment of HIV infection convened by theDepartment of Health and Human Services; October, 2006. Available at: http://aidsinfo.nih.gov/contentfiles/AduItandAdolescentGL.pdf Accessed Novem ber 10, 2006.
   Google Scholar
• Smeaton L, DeGruttola V, Robbins G, Shafer R, ACTG 384 (AIDS Clinical Trials Group). A strategy trial compar-ing consecutive treatments for HIV-1. Control Clin Trials. 2001;22(2)1 42–159.
   PubMedGoogle Scholar
• Haas D, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretro-viral therapy: a randomized comparative pilot trial. AIDS. 2003;17(9):1339–1349.
   PubMed Web of Science ®Google Scholar
• Hammer S, Vaida F, Bennett K, et al. Dual vs. single prote-ase inhibitor therapy following antiretroviral treatment fail-ure: a randomized trial. JAMA. 2002;288(2):169–180.
   PubMed Web of Science ®Google Scholar
• Gulick R, Hu X, Fiscus S, et al. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. J Infect Dis. 2002 ; 186(5):626–633.
   PubMed Web of Science ®Google Scholar
• Palella FJ, Chmiel J, Moorman A, et al. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS. 2002;16(12): 1617–1626.
   PubMed Web of Science ®Google Scholar
• Phillips A, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiret-roviral therapy in previously drug-naive individuals. AIDS. 2001 ;15(18):2379–2384.
   PubMed Web of Science ®Google Scholar
• Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Ann Intern Med. 2000;160(8): 1123–1132.
   Web of Science ®Google Scholar
• Celantano D, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280(6):544–546.
   PubMed Web of Science ®Google Scholar
• Ostrop N, Hallett K, Gill M. Long-term patient adherence to antiretroviral therapy. Ann Pharmacother. 2000;34(6):703–709.
   PubMed Web of Science ®Google Scholar
• Miller LG, Golin CE, Hays R, et al. Impact of antiretro-viral regimen switches on adherence. HIV Clin Trials. 2002;3(5):355–360.
   PubMedGoogle Scholar
• Wood E, Montaner JS, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169(7):656–661.
   PubMed Web of Science ®Google Scholar
• Bartlett J, Fath M, DeMasi R, et al. An updated meta-analy-sis of triple combination therapy in antiretroviral—naive HIV-infected adults. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections (CR01); February 22–25, 2005; Boston.
   Google Scholar
• Altice FL, Springer S. Reply to Babudieri et al. Clin Infect Dis. 2005;40:322–323.
   Web of Science ®Google Scholar
• Baillargeon J, Borucki MJ, Zepeda S, Jenson HB, Leach CT. Antiretroviral prescribing patterns in the Texas prison system. Clin Infect Dis. 2000;31(6):1476–1481.
   PubMed Web of Science ®Google Scholar
• Stephenson BL, Wohl DA, Golin CE, Tien HC, Stewart P, Kaplan AH. Effect of release from prison and re-incarcera-tion on the viral loads of HIV-infected individuals. Public Health Rep. 2005;120(1):84–88.
   PubMed Web of Science ®Google Scholar
• Celentano D, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280(6):544–546.
   PubMed Web of Science ®Google Scholar
• Strathdee S, Palepu A, Cornelisse P, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280(6):547–549.
   PubMed Web of Science ®Google Scholar
• Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudi-nal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002 ;16(5):767–774.
   PubMed Web of Science ®Google Scholar
• Altice FL, Mostashari F, Friedland G. Trust and acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol. 200128(1):47–58.
   Google Scholar
• Flanigan T, Rich J, Spaulding A. HIV care among incarcer-ated persons: a missed opportunity. AIDS. 1999;13: 2475–2476.
   PubMed Web of Science ®Google Scholar